NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$11.13 USD
-0.38 (-3.30%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $11.14 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVCR 11.13 -0.38(-3.30%)
Will NVCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NVCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVCR
NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
NVCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
What Makes NovoCure (NVCR) a New Buy Stock
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Other News for NVCR
NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead
Insider Buying: Christoph Brackmann Acquires 20,000 Shares of NovoCure Ltd (NVCR)
NovoCure's Wearable Oncology Edge And Compelling Valuation
Top 3 Health Care Stocks That May Explode In July
Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Target Cut | NVCR Stock News